Monoclonal antibodies blocking IL-23 show efficacy in adults with moderate-to-severe psoriasis, such as ustekinumab (Ust) targeting IL-12/IL-23p40 and guselkumab (Gus), tildrakizumab (Til), and risankizumab (Ris) targeting IL-23p19. This evidence concerns the gene IL37 and psoriasis.